Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $23.00 price objective on the stock.

Separately, Oppenheimer boosted their price target on shares of Protara Therapeutics from $26.00 to $30.00 and gave the company an outperform rating in a report on Monday, April 22nd.

Protara Therapeutics Stock Down 1.4 %

Shares of NASDAQ:TARA opened at $2.83 on Monday. The business’s 50 day moving average is $3.53 and its 200 day moving average is $2.57. The stock has a market cap of $32.35 million, a P/E ratio of -0.76 and a beta of 1.80. Protara Therapeutics has a 52-week low of $1.04 and a 52-week high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.13. On average, sell-side analysts anticipate that Protara Therapeutics will post -3.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Protara Therapeutics

A hedge fund recently bought a new stake in Protara Therapeutics stock. Oppenheimer & Co. Inc. acquired a new position in Protara Therapeutics, Inc. (NASDAQ:TARA) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned about 0.09% of Protara Therapeutics as of its most recent SEC filing. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.